Taysha Gene Therapies (TSHA) Liabilities and Shareholders Equity (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $300.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 117.08% year-over-year to $300.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 90.41% YoY), and the FY2025 full-year result was $343.3 million, up 114.09% from the prior year.
• Liabilities and Shareholders Equity eased to $300.4 million in Q1 2026, from $343.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $343.3 million in Q4 2025 to a low of $81.5 million in Q2 2023.
• A 5-year average of $189.6 million and a median of $166.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity sank 53.76% in 2022 and soared 145.75% in 2024, its largest moves.
• Tracing TSHA's Liabilities and Shareholders Equity over 5 years: stood at $126.3 million in 2022, then jumped by 36.79% to $172.7 million in 2023, then decreased by 7.16% to $160.4 million in 2024, then surged by 114.09% to $343.3 million in 2025, then declined by 12.52% to $300.4 million in 2026.
• Business Quant data shows TSHA's Liabilities and Shareholders Equity at $300.4 million in Q1 2026, $343.3 million in Q4 2025, and $316.6 million in Q3 2025.